article thumbnail

ANDA Litigation Settlements - Summer 2021

JD Supra Law

This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that are filed pursuant to the Hatch-Waxman Act. By: Robins Kaplan LLP

article thumbnail

Movie Companies Sue Lawyer in Dispute Over Piracy Settlement Cash

TorrentFreak

For companies whose movies are downloaded and shared illegally, solutions have been developed that allow them to monitor suspected pirates and track them back to their ISPs, before obtaining their identities and making a settlement offer to end the risk of a full-blown lawsuit.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Genentech and Tanvex Reach Settlement in Principle in Trastuzumab BPCIA Litigation

JD Supra Law

On January 6, 2023, Genentech and Tanvex reached a settlement in principle to resolve all claims with respect to Genentech’s BCPIA complaint.

article thumbnail

Genentech and Tanvex Reach Settlement in Principle in Trastuzumab BPCIA Litigation

LexBlog IP

On January 6, 2023, Genentech and Tanvex reached a settlement in principle to resolve all claims with respect to Genentech’s BCPIA complaint. The post Genentech and Tanvex Reach Settlement in Principle in Trastuzumab BPCIA Litigation appeared first on Big Molecule Watch.

article thumbnail

Rightscorp Taps Indie Labels to Fuel New Wave of Piracy Settlement Action

TorrentFreak

By attaching settlement demands to DMCA notices sent to ISPs, Rightscorp hoped these would be forwarded intact to subscribers. After reporting even more losses a year later, Rightscorp stared into the abyss, but then a key event threw it a lifeline. At the time, Rightscorp was a publicly listed company but was hemorrhaging money.

article thumbnail

Genentech BPCIA Trastuzumab Case Against Tanvez Dismissed After Settlement

JD Supra Law

As previously reported, Genentech and Tanvex reached an agreement in January 2022 to settle BPCIA litigation relating to Tanvex’s biosimilar of HERCEPTIN (trastuzumab). On February 9, the court entered an order dismissing all claims in the case. By: Goodwin

article thumbnail

Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation

JD Supra Law

Samsung Bioepis recently reported that it has signed a settlement and license agreement with Johnson & Johnson (“J&J”) in the United States relating to SB17, Samsung Bioepis’s ustekinumab biosimilar to J&J’s STELARA®. If SB17 is approved by the FDA, the license period in the United States will begin on February 22, 2025.